DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors

Hirohata, T; Asano, Kenichiro; Ogawa, Yoshikazu; Takano, Shingo; Amano, Kosaku; Isozaki, Osamu; Iwai, Yoshiyasu; Sakata, Kiyohiko; Fukuhara, Noriaki; Nishioka, Hiroshi; Yamada, Shozo; Fujio, Shingo; Arita, Kazunori; Takano, Koji; Tominaga, Atsushi; Hizuka, Naomi; Ikeda, Hidetoshi; Yoshiyuki Osamura, R.; Tahara, Shigeyuki; Ishii, Yudo; Kawamata, Takakazu; Shimatsu, Akira; Teramoto, Akira; Matsuno, Akira

doi:10.1210/jc.2012-2924

Public

DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors

Published in The Journal of Clinical Endocrinology & Metabolism • Jan 30, 2013

Authors:

T Hirohata

Kenichiro Asano

Yoshikazu Ogawa

Abstract

CONTEXT: Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be effective against atypical pituitary adenomas (APAs) and pituitary carcinomas (PCs). OBJECTIVE: The clinical and pathological characteristics ...

Subject

Temozolomide

MSH6

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!